BioXcel Therapeutics, Inc. (BTAI)
NASDAQ: BTAI · Real-Time Price · USD
1.480
-0.130 (-8.07%)
At close: Mar 6, 2026, 4:00 PM EST
1.470
-0.010 (-0.66%)
After-hours: Mar 6, 2026, 7:59 PM EST
BioXcel Therapeutics Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for BioXcel Therapeutics stock have an average target of 25.33, with a low estimate of 4.00 and a high estimate of 66. The average target predicts an increase of 1,611.49% from the current stock price of 1.48.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for BioXcel Therapeutics stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 1 | 1 | 1 | 1 | 1 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $10 → $6 | Strong Buy | Maintains | $10 → $6 | +305.41% | Mar 5, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +575.68% | Sep 15, 2025 |
| Mizuho | Mizuho | Hold Maintains $2 → $4 | Hold | Maintains | $2 → $4 | +170.27% | Sep 12, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +575.68% | Aug 28, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +575.68% | Aug 19, 2025 |
Financial Forecast
Revenue This Year
591.19K
from 2.27M
Decreased by -73.91%
Revenue Next Year
2.14M
from 591.19K
Increased by 261.81%
EPS This Year
-6.67
from -23.51
EPS Next Year
-2.98
from -6.67
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 669,900 | 4.3M | ||||
| Avg | 591,192 | 2.1M | ||||
| Low | 490,000 | 392,000 |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -70.4% | 628.2% | ||||
| Avg | -73.9% | 261.8% | ||||
| Low | -78.4% | -33.7% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -5.97 | -1.46 | ||||
| Avg | -6.67 | -2.98 | ||||
| Low | -7.38 | -4.39 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.